Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | YAP1 | P46937 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30032071 | 1.00 | CCNT1 (0.38) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL28901669 | 0.92 | EGFR (0.37) | EGFRMEN1MAPTKMT2A | |
| SCHEMBL25583973 | 0.88 | CCNT1 (0.46) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL23783305 | 0.85 | TLR9 (0.37) | TLR9TLR7STSACHEYAP1 | |
| SCHEMBL30031986 | 0.85 | TLR9 (0.37) | TLR9TLR7STSACHEYAP1 | |
| SCHEMBL23783155 | 0.83 | GPR119 (0.46) | STSYAP1GPR119PRMT5 | |
| SCHEMBL30032767 | 0.83 | GPR119 (0.46) | STSYAP1GPR119PRMT5 | |
| SCHEMBL25846238 | 0.82 | AXL (0.35) | CCNT1CDK2CDK9EGFRMEN1 | |
| SCHEMBL30898917 | 0.82 | PRMT5 (0.38) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL30796702 | 0.81 | STS (0.40) | CCNT1CCNA2CDK2CDK9CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | CCNT1 2161/4885CCNA2 1990/4885CDK2 1278/4885 |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | CCNT1 2161/4885CCNA2 1990/4885CDK2 1278/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | CCNT1 2161/4885CCNA2 1990/4885CDK2 1278/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | CCNT1 2161/4885CCNA2 1990/4885CDK2 1278/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | CCNT1 2161/4885CCNA2 1990/4885CDK2 1278/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | CCNT1 2161/4885CCNA2 1990/4885CDK2 1278/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | CCNT1 3019/4885CCNA2 2890/4885CDK2 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.